Dr. Blaine M. Hackman, Associate, Dechert LLP to Speak at The Knowledge Group’s Obviousness-Type Double Patenting: Navigating the Ever-Evolving Landscape LIVE Webcast

Top Quote Dr. Blaine M. Hackman, Associate, Dechert LLP will speak at its webcast entitled, “Obviousness-Type Double Patenting: Navigating the Ever-Evolving Landscape” scheduled for October 1, 2019 from 12:00 pm to 2:00 pm ET. End Quote
  • (1888PressRelease) September 17, 2019 - The Knowledge Group, the leading producer of regulatory focused webcasts, has announced today that Dr. Blaine M. Hackman, Associate, Dechert LLP will speak at its webcast entitled, “Obviousness-Type Double Patenting: Navigating the Ever-Evolving Landscape.” This event is scheduled for October 1, 2019 from 12:00 pm to 2:00 pm ET.

    For further details, please visit: https://www.theknowledgegroup.org/webcasts/obviousness-type-double-patenting/

    About Dr. Blaine M. Hackman
    Blaine M. Hackman Ph.D. currently focuses his practice on patent counseling, prosecution, and post-grant proceedings, including Inter Partes Reviews (IPRs) and Post-Grant Reviews (PGRs) before the Patent Trial and Appeal Board (PTAB), in the areas of pharmaceuticals and biotechnology. Dr. Hackman has represented pharmaceutical and biotechnology clients in intellectual property litigation (including Hatch-Waxman proceedings) and post-grant proceedings on behalf of petitioners and patent owners. He has also prosecuted patents in a variety of technologies, including small molecule and protein therapies, nanotechnology, diagnostic imaging, and analytical chemistry.

    Dr. Hackman has published and presented on intellectual property related issues, and he was recognized for authoring an Article of the Month by the Licensing Executive Society International Journal, les Nouvelles. He has also been recognized as a Rising Star by Super Lawyers in their intellectual property category in 2017 and 2018.

    About Dechert LLP
    Dechert is a leading global law firm with 26 offices around the world. We deliver deep legal expertise and practical commercial judgment for high-stakes matters in sectors with the greatest complexities, intricacies and regulatory demands.
    Dechert is organized by practice area, not geography. This approach allows us to deliver a team responsive to unique project requirements and provide the resources needed to complete work with speed-to-market execution. Our lawyers understand the current marketplace, as well as rapidly evolving commercial and regulatory challenges, making us a preeminent full-service advisor.

    We are a global, mobile workforce of diverse skills and areas of expertise. We use a project management approach to our workflow, enabling us to quickly adapt to changing client needs, maximize technology, drive efficiency and deliver value to our clients.

    The emergence of new court rulings in the U.S. and Canada continues to shape the applicability and scope of the obviousness-type double patenting (ODP) doctrine, which is meant to prevent patentees from unjustly extending patent rights by owning multiple patents on the same invention. Recently, the U.S. Court of Appeals for the Federal Circuit issued two significant decisions - Novartis AG v. Ezra Ventures LLC and Novartis Pharmaceuticals Corp. v. Breckenridge Pharmaceutical Inc. - which provide guidance on when ODP does not invalidate patent term extensions (PTEs). In Canada, where there is no terminal disclaimer, upcoming changes to the Patent Rules will impact procedures commonly used to prevent double patenting.

    Counsel to patent applicants and owners should be in the know of the recent court rulings and other developments involving ODP to better manage potential threats and opportunities regarding patent term and validity.

    This LIVE Webcast produced by The Knowledge Group will provide patent practitioners with an in-depth analysis of the evolving ODP landscape in the USA and Canada. They will examine the implications of recent U.S. Court rulings in Ezra and Breckenridge and other ODP updates while offering insights on how to best protect a client’s interests from significant ODP issues in the U.S. and Canada.

    Some of the major topics that will be covered in this course are:
    • Recent Court Rulings:
    o Novartis AG v. Ezra Ventures LLC
    o Novartis Pharmaceuticals Corp. v. Breckenridge Pharmaceutical Inc.
    • Implications of Recent Trends and Developments
    • Managing Potential Threats and Opportunities
    • Best Practices and Strategies

    About The Knowledge Group
    The Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register to an event, please visit: http://theknowledgegroup.org/.

  • FB Icon Twitter Icon In-Icon
Contact Information